Several NHS hospitals are preparing to use an AI-powered blood test to help assess women referred for possible womb cancer before invasive checks are carried out.
According to The Guardian, around 90,000 postmenopausal women in England are referred by GPs each year for checks after experiencing heavy bleeding. About 10,000 women are diagnosed with womb cancer annually, and around 2,700 die from the disease.
How the PinPoint test works
The test, developed by Leeds-based PinPoint Data Science, uses machine learning to assess cancer risk from blood markers. It classifies patients as low, elevated, or high risk based on an analysis of around 30 markers.
PinPoint said the test costs around £30 and gives clinicians a risk score for use within existing cancer referral pathways. The score can help inform whether a patient is monitored, referred for further investigation, or prioritised for faster assessment.
PinPoint describes the tool as a multi-cancer test. The company said it has been used across gynaecological, lung, upper gastrointestinal, head and neck, and lower gastrointestinal cancer pathways.
The test is being introduced after a trial involving 16,481 patients referred through urgent suspected cancer pathways across Yorkshire. The trial included women referred with symptoms that raised concern about possible womb or gynaecological cancer.
About one in 10 women referred because of heavy bleeding were found to have cancer, according to the reported trial results.
PinPoint said the test correctly identified 99.1% of cancers as elevated or high risk and delivered a negative predictive value of 99.8% for women in the lowest-risk group.
Mid Yorkshire NHS Teaching Trust plans to use the test for six types of gynaecological or upper gastrointestinal cancer. Leeds Teaching Hospitals NHS Trust plans to use it for gynaecological cancer.
Current diagnostic pathway
Under the current pathway, women referred for suspected reproductive system cancers usually undergo a pelvic examination that includes a transvaginal ultrasound scan. The procedure involves inserting an ultrasound probe into the vagina to measure the thickness of the womb lining, and some women find it uncomfortable or painful.
If doctors continue to suspect cancer, patients can then be referred for further checks, including a biopsy and hysteroscopy, an examination of the inside of the womb. PinPoint said its test is intended to identify women at very low risk before those procedures are used.
The company said the test could spare about one in five referred women from needing a transvaginal ultrasound scan. That would amount to around 18,000 women a year in England.
Professor Sean Duffy, chief medical officer at PinPoint Data Science and a former NHS England national clinical director for cancer, said the test’s value lies in ruling out women at very low risk.
Dr Jacinta Walsh, a GP at King’s Medical Practice in Normanton, West Yorkshire, said patients can require up to six GP visits before cancer is…
Source link
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We blogs.grocliq.com want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on for any glitch kindly connect at [email protected]
